New AI Tools Help Accelerate Tuberculosis Research
Researchers in the Global South will receive access to AI-driven drug discovery models to target tuberculosis.
Updated on Oct. 15, 2026 in Diseases — General
Live Poll
Should private AI developers prioritize making their drug discovery tools open-access for global health research?
DaltonTx has received a grant from the Gates Foundation to develop artificial intelligence models for tuberculosis drug discovery. The initiative aims to provide researchers in the Global South with open-access tools and training to accelerate the development of new treatments.
Why it matters
Tuberculosis remains a significant global health burden, particularly in low- and middle-income countries. This initiative seeks to lower the barriers to drug discovery by providing affordable, high-tech tools to regions where infectious disease research is critically needed.
The project analyzes hundreds of essential and vulnerable Mycobacterium tuberculosis genes using protein structure prediction and machine learning. While this approach is projected to reduce discovery costs, the final therapeutic efficacy remains to be determined.
The players
DaltonTx
A biotechnology firm developing computational tools and artificial intelligence models for drug discovery.
Gates Foundation
A philanthropic organization that funds global health initiatives to combat infectious diseases.
Ersilia
A non-profit organization that hosts an open-access model hub for computational biology tools.
The details
The project integrates machine learning with physics-based modelling to predict protein structures, helping to identify chemical starting points for new therapies. Researchers will distribute these validated models, workflows, and datasets through the Ersilia Model Hub to ensure global access. The program also facilitates knowledge transfer through workshops designed for investigators in the Global South.
Timeline
October 15, 2026: DaltonTx announced the receipt of the grant.
Health Landscape
This project represents a shift toward democratizing high-tech computational drug discovery. The project marks a significant expansion of the Ersilia Model Hub, which provides open-access computational tools for global health.
This development focuses on the research and discovery phase of infectious disease treatment, rather than immediate clinical care. While these tools may eventually lead to new therapies, patients should continue to consult their physicians regarding existing, evidence-based tuberculosis treatment protocols.
The takeaway
Artificial intelligence is increasingly becoming a vital resource for researchers tackling infectious diseases globally. Tracking advancements in drug discovery remains a key metric for understanding the future of TB treatment access.
Further reading
For more information on current developments in infection research, visit Diseases — General.
Live Poll
Should private AI developers prioritize making their drug discovery tools open-access for global health research?
